recombin
subviru
particl
retain
similar
antigen
featur
authent
viral
capsid
thu
appli
nonrepl
subunit
vaccin
viral
infect
ill
addit
selfassembl
polyval
subvir
particl
excel
platform
display
foreign
antigen
immun
enhanc
vaccin
develop
subvir
particlebas
vaccin
noninfecti
thu
safer
convent
live
attenu
inactiv
vaccin
sever
vlp
vaccin
avail
market
numer
other
includ
dual
vaccin
one
pathogen
clinic
preclin
develop
articl
provid
updat
effort
recombin
subviru
particl
retain
similar
antigen
featur
authent
viral
capsid
thu
appli
nonrepl
subunit
vaccin
viral
infect
ill
addit
selfassembl
polyval
subvir
particl
excel
platform
display
foreign
antigen
immun
enhanc
vaccin
develop
subvir
particlebas
vaccin
noninfecti
thu
safer
convent
live
attenu
inactiv
vaccin
sever
vlp
vaccin
avail
market
numer
other
includ
dual
vaccin
one
pathogen
clinic
preclin
develop
articl
provid
updat
effort
virus
share
common
spheric
rodshap
capsid
built
multipl
subunit
capsid
protein
encapsul
viral
genom
bioengin
technolog
viral
capsid
protein
produc
vitro
result
selfassembl
empti
viruslik
particl
vlp
review
addit
smaller
particl
less
subunit
produc
virus
express
portion
major
viral
capsid
protein
artifici
subvir
particl
retain
structur
antigen
properti
nativ
virus
includ
virusspecif
molecular
pattern
high
densiti
bcell
tcell
epitop
induc
potent
innat
humor
cellular
immun
respons
respect
anim
human
thu
subvir
particl
excel
sourc
materi
vaccin
develop
mani
virus
associ
diseas
vlp
usual
made
eukaryot
express
system
includ
baculovirusinsect
cell
yeast
mammalian
cell
smaller
subvir
particl
hepat
b
viru
hbv
vlp
produc
e
coli
express
system
tabl
costeffect
sevral
subvir
particlebas
vaccin
current
avail
market
mani
other
clinic
preclin
develop
selfassembl
polyval
subvir
particl
also
excel
platform
antigen
present
enhanc
immunogen
genet
engin
chemic
conjug
heterolog
antigen
peptid
epitop
insert
conjug
onto
surfac
subvir
particl
polyval
present
foreign
antigen
epitop
subvir
particl
lead
enhanc
immunogen
provid
effect
approach
novel
vaccin
develop
hand
immunogen
subvir
particl
gener
maintain
without
disruppt
foreign
insert
thu
chimer
particl
use
dual
even
multival
vaccin
two
pathogen
number
chimer
particl
preclin
develop
point
new
direct
highli
effici
low
cost
vaccin
major
infecti
diseas
differ
subvir
particl
tabl
subvir
particl
easili
produc
laboratori
tabl
sever
reach
market
effect
vaccin
success
scaledup
product
good
manufactur
practic
gmp
subvir
particl
excel
immunogen
induc
strong
humor
cellular
immun
respons
shown
numer
studi
tabl
immun
subvir
particl
vaccin
differ
anim
speci
human
variou
rout
intranas
intramuscular
intraperiton
administr
stimul
high
antibodi
well
high
prolif
cytotox
lymphocyt
ctl
respons
tabl
featur
support
subvir
partciel
highli
effici
vaccin
mani
infect
diseas
addit
vaccin
subvir
particl
also
use
vaccin
platform
present
foreign
antigen
small
peptid
epitop
heterolog
pathogen
novel
vaccin
develop
highli
stabl
structur
subvir
particl
toler
exogen
insert
achiev
either
recombin
dna
technolog
chemic
conjug
nativ
antigen
properti
insert
antigen
epitop
usual
preserv
surfac
chimer
particl
immunogen
antigenepitop
significantli
enhanc
polyval
natur
subvir
particl
function
adjuv
addit
major
antigen
determin
subvir
particl
carrier
gener
preserv
thu
result
chimer
particl
use
dual
vaccin
pathogen
insert
carrier
numer
chimer
particl
antigen
epitop
insert
surfac
produc
tabl
foreign
antigen
usual
insert
surfac
loop
subvir
particl
capac
foreign
insert
subvir
particledepend
maxim
insert
residu
green
fluoresc
protein
gfp
hbv
vlp
residu
antigen
rotaviru
p
particl
nov
report
select
proper
site
subvir
particl
insert
exogen
antigen
andor
epitop
import
gener
stabl
chimer
particl
distal
end
flexibl
surfac
loop
gener
good
choic
hbv
vlp
extens
studi
vaccin
platform
present
heterolog
antigen
epitop
chimer
vlp
vaccin
reach
phase
iii
two
phase
human
trial
one
rt
malaria
vaccin
glaxosmithklin
compris
ctermin
half
residu
mani
chimer
subvir
particlebas
vaccin
preclin
evalu
includ
deriv
vlp
polyomavirus
cowpea
mosaic
virus
flock
hous
viru
nov
nonrepl
subunit
vaccin
import
option
mani
viral
pathogen
particularli
vitro
cultiv
system
remain
lack
human
nov
danger
cultur
variola
viru
ebola
viru
also
choic
futur
vaccin
avoid
safeti
concern
convent
live
attenu
inactiv
vaccin
safe
vaccin
erad
polioviru
recent
report
increas
risk
intussuscept
two
live
attenu
rotaviru
vaccin
vaccin
children
new
exampl
concern
could
prevent
nonrepl
subunit
vaccin
howev
base
current
technolog
seem
possibl
produc
subvir
particl
known
viral
pathogen
thu
technolog
subvir
particlebas
antigen
present
provid
import
strategi
vaccin
develop
viral
pathogen
shown
two
tabl
mani
subvir
particl
capabl
antigen
carrier
sinc
major
antigen
determin
mani
viral
pathogen
known
tabl
would
straightforward
design
produc
new
vaccin
take
advantag
technolog
past
experi
suggest
success
chimer
vaccin
may
reli
certain
level
structur
andor
chemic
compat
carrier
insert
antigen
simpl
solut
technic
challeng
problem
occur
attempt
carrierantigen
combin
encourag
addit
modif
carrier
vector
includ
short
flexibl
peptid
adaptor
two
arm
surfac
loop
option
furthermor
maxim
size
insert
antigen
may
vari
among
differ
carrier
therefor
select
proper
carrier
larger
antigen
also
recommend
final
select
appropri
carrierantigen
combin
consid
base
target
pathogen
host
popul
exampl
nov
rotavirus
caus
acut
gastroenter
children
select
nov
p
particl
carrier
present
rotaviru
surfac
antigen
ideal
combin
highli
effect
dual
vaccin
two
import
caus
acut
gastroenter
children
subvir
particlebas
vaccin
may
immunogen
replic
virus
follow
natur
infect
thu
develop
strategi
maxim
efficaci
subvir
vaccin
import
optim
vaccin
formul
vaccin
regim
may
key
includ
increas
vaccin
dose
dosag
identif
best
administr
rout
use
appropri
adjuv
case
antigenpresent
approach
use
ration
design
vaccin
increas
copi
number
insert
antigensepitop
subvir
particl
carrier
consid
addit
insert
univers
immunu
stimul
element
cell
epitop
may
consid
current
product
subvir
particl
reli
eukaryot
express
system
baculoviru
insect
cell
yeast
mammalian
cell
sinc
bacteria
produc
subvir
particl
lower
cost
attempt
improv
prokaryot
express
system
product
subvir
particl
would
help
reduc
cost
vaccin
deliveri
develop
countri
hpv
readili
produc
e
coli
excel
qualiti
yield
sinc
viral
pathogen
preval
develop
countri
studi
develop
subvir
particl
costeffect
vaccin
vaccin
platform
broad
applic
develop
world
highli
signific
final
new
concept
vaccin
deliveri
edibl
vaccin
produc
transgen
vegetbl
contain
relat
subvir
particl
explor
fang
h
tan
xia
wang
l
jiang
x
noroviru
p
particl
effici
elicit
innat
humor
cellular
immun
plo
one
studi
describ
data
noroviru
p
particl
effici
elicit
innat
humor
cellular
immun
typic
exampl
subvir
particl
induc
variou
immun
respons
